Satellos Bioscience (MSLE) Stock Price, News & Analysis

Company Overview

Satellos Bioscience Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease.

The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy. Satellos is evaluating whether its approach can restore or enhance the function of muscle stem cells and improve the body’s ability to regenerate damaged muscle.

Satellos Bioscience is headquartered in Canada and was established to advance research into muscle stem-cell biology and potential treatments for serious neuromuscular diseases. The company’s programs remain in development, and its therapies have not been established as safe or effective for commercial use.

Key Stats

• Today's Range: $7.29 to $7.74
• 50-Day Range: $7.34 to $10.19
• 52-Week Range: $5.30 to $13.39
• Volume: 59,851 shs
• Average Volume: 60,296 shs
• Market Capitalization: $158.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.60
• Consensus Rating: Moderate Buy

Satellos Bioscience Stock Analysis - MarketRank™

Satellos Bioscience scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Satellos Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Satellos Bioscience has a consensus price target of $20.60, representing about 175.0% upside from its current price of $7.49.

Amount of Analyst Coverage

Satellos Bioscience has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Satellos Bioscience are expected to decrease in the coming year, from ($1.86) to ($1.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Satellos Bioscience is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Satellos Bioscience has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of Satellos Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Satellos Bioscience has a short interest ratio ("days to cover") of 1.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Satellos Bioscience has recently increased by 28.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Satellos Bioscience does not currently pay a dividend.

Dividend Growth

Satellos Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.22

News Sentiment

Satellos Bioscience has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Satellos Bioscience this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Satellos Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Satellos Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

37.90% of the stock of Satellos Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Satellos Bioscience has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MSLE
• CIK: 1421642
• Web: satellos.com
• Phone: (647) 660-1780
• Fax: 604-602-9699
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Satellos Bioscience: $20.60
• High Price Target: $24.00
• Low Price Target: $18.00
• Potential Upside/Downside: +175.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.97%
• Return on Assets: -65.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.22
• Quick Ratio: 11.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.80 per share
• Price / Book: 4.16

Miscellaneous

• Outstanding Shares: 21,220,000
• Free Float: 13,175,000
• Market Cap: $158.94 million
• Optionable: N/A
• Beta: 1.51